Safety Differences across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

The authors discuss the efficacy and safety of second-generation androgen receptor inhibitors and propose that for patients with nonmetastatic castration-resistant prostate cancer, safety considerations for these treatments are especially important.